行情

CBM

CBM

凯姆布雷克斯
NYSE

实时行情|Nasdaq Last Sale

59.51
+0.02
+0.03%
盘后: 59.51 0 0.00% 16:00 10/18 EDT
开盘
59.43
昨收
59.49
最高
59.59
最低
59.43
成交量
109.68万
成交额
--
52周最高
60.29
52周最低
33.80
市值
20.07亿
市盈率(TTM)
38.42
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CBM 新闻

  • UPDATE 1-Private equity firm Permira closes new fund at $12 bln
  • Reuters.5天前
  • ALXN vs. CBM: Which Stock Should Value Investors Buy Now?
  • Zacks.10/10 14:30
  • INVESTOR ALERT: Monteverde & Associates PC Continues to Investigate the Following Transactions
  • ACCESSWIRE.09/26 21:45
  • Bragar Eagel & Squire, P.C. Announces that it is Investigating the Boards of Directors of Highlands, Cambrex, Two River, and Carbon Black on behalf of Stockholders and Encourages Investors to Contact the Firm
  • GlobeNewswire.09/25 22:17

更多

所属板块

制药
-0.90%
制药与医学研究
-0.94%

热门股票

名称
价格
涨跌幅

CBM 简况

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.
展开

Webull提供Cambrex Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。